evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

13 questions · 13 findings · 2 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 46.2%GRADE not reported 2 · 15.4%Very low 5 · 38.5%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Death Analysis 1.1 · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Clinically relevant non‐major bleeding ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes incidence of hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

1 finding from 1 review

Summary of findings: Antithrombin III plus heparin vs heparin

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes frequency of adverse events ( compared with heparin alone (very low certainty).

1 finding from 1 review